Anúncio
Anúncio
KLRS
Kalaris Therapeutics, Inc. Common Stock
9.82
USDPatrocinado
+1.56
+18.95%
09 de jan., 15:58 UTC -5
Encerrado
Pós-Mercado
9.99
+0.17
+1.68%
Relatórios de Lucros KLRS
Rácio de surpresa positiva
KLRS separação 10 de 19 últimas estimativas.
53%
Próximo Relatório
Data do Próximo Relatório
05 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.54
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/-15.63%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/--
Kalaris Therapeutics, Inc. Common Stock earnings per share and revenue
On 12 de nov. de 2025, KLRS reported earnings of -0.64 USD per share (EPS) for Q3 25, beating the estimate of -0.66 USD, resulting in a 3.89% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analistas forecast an EPS of -0.54 USD, with revenue projected to reach -- USD, implying an diminuir of -15.63% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Kalaris Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kalaris Therapeutics, Inc. Common Stock reported EPS of -$0.64, beating estimates by 3.89%, and revenue of $0.00, 0% as expectations.
How did the market react to Kalaris Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -2.17%, changed from $5.07 before the earnings release to $4.96 the day after.
When is Kalaris Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 05 de mar. de 2026.
What are the forecasts for Kalaris Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analistas, Kalaris Therapeutics, Inc. Common Stock is expected to report EPS of -$0.54 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio